Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer
Current Oncology · 24.06.2026 · 33 (7) · 384
DOI: 10.3390/curroncol33070384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.06.2026. Verfasst von Chian-Wei Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Immunotherapy. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, National Cheng Kung University Hospital.
Abstract (Originalsprache)
Patients with BRAFV600E-mutated metastatic lung cancer benefit from both BRAF plus MEK inhibitors and immune checkpoint inhibitor (ICI)–chemotherapy. This study evaluated the cost-effectiveness of first-line ICI–chemotherapy compared with BRAF plus MEK inhibitors in these patients. This economic analysis, with a 15-year time horizon and an annual 3% discount, was conducted from the perspective of the healthcare sectors in Taiwan and the US. Simulated patients were entered into partitioned survival models upon initiation of first-line therapies. The model inputs were derived from the FRONT-BRAF study (progression-free/overall survival, adverse events, and subsequent therapies), insurance payments or retail prices (costs of drugs, physician visits, monitoring, adverse events, and end-of-life care), and a hospital cohort (health utility). Deterministic and probabilistic analyses were performed. The incremental cost-effectiveness ratios (ICERs) of ICI–chemotherapy compared with BRAF plus MEK inhibitors (Taiwan: $73,561/QALY; US: $290,279/QALY) exceeded the willingness-to-pay (WTP) thresholds (Taiwan: $70,000/QALY; US: $150,000/QALY). The drug costs of subsequent therapies and the utility values of the progressive-disease state were the major determinants of ICERs. In Taiwan, ICI–chemotherapy had a 41.0% probability of being cost-effective at the WTP threshold. ICI–chemotherapy had a higher probability of being cost-effective than BRAF plus MEK inhibitors when the WTP exceeded $300,000/QALY in the US. Our analysis suggests that, despite the longer survival of first-line ICI–chemotherapy compared with BRAF plus MEK inhibitors, ICI–chemotherapy is not a cost-effective strategy for patients with BRAFV600E-mutated metastatic lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
- National Cheng Kung University Hospital Cancer Center, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
- Department of Statistics, College of Management, National Cheng Kung University, Tainan 701, Taiwan.
ORCID-Profile: Li-Jun Chen, Szu-Chun Yang
Förderung
- National Science and Technology Council
- National Cheng Kung University Hospital
Zitieren
APA
Chen, C. W., Tsai, J. H., Tsai, S. H., Chen, L. J., & Yang, S. C. (2026). Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer. Current Oncology, 33(7), 384. https://doi.org/10.3390/curroncol33070384
Vancouver
Chen CW, Tsai JH, Tsai SH, Chen LJ, Yang SC. Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer. Current Oncology. 2026;33(7):384. doi:10.3390/curroncol33070384
BibTeX
@article{Chen2026,
author = {Chen, Chian-Wei and Tsai, Jui-Hung and Tsai, Sheng-Han and Chen, Li-Jun and Yang, Szu-Chun},
title = {Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAFV600E-Mutated Metastatic Lung Cancer},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {384},
doi = {10.3390/curroncol33070384}
}
EUVIMED